OARSI Clinical Trials Recommendations: Soluble Biomarker Assessments in Clinical Trials in Osteoarthritis

Overview

Journal Osteoarthritis Cartilage

Specialties Orthopedics
Rheumatology

Date 2015 May 9

PMID 25952342

Citations 44

Authors

V B Kraus

F J Blanco

M Englund

Y Henrotin

L S Lohmander

E Losina

P Onnerfjord

S Persiani

Affiliations

Soon will be listed here.

Abstract

The objective of this work was to describe requirements for inclusion of soluble biomarkers in osteoarthritis (OA) clinical trials and progress toward OA-related biomarker qualification. The Guidelines for Biomarkers Working Group, representing experts in the field of OA biomarker research from both academia and industry, convened to discuss issues related to soluble biomarkers and to make recommendations for their use in OA clinical trials based on current knowledge and anticipated benefits. This document summarizes current guidance on use of biomarkers in OA clinical trials and their utility at five stages, including preclinical development and phase I to phase IV trials. As demonstrated by this summary, biomarkers can provide value at all stages of therapeutics development. When resources permit, we recommend collection of biospecimens in all OA clinical trials for a wide variety of reasons but in particular, to determine whether biomarkers are useful in identifying those individuals most likely to receive clinically important benefits from an intervention; and to determine whether biomarkers are useful for identifying individuals at earlier stages of OA in order to institute treatment at a time more amenable to disease modification.

Citing Articles

Mitochondrial Role on Cellular Apoptosis, Autophagy, and Senescence during Osteoarthritis Pathogenesis.

Dalmao-Fernandez A, Hermida-Gomez T, Nogueira-Recalde U, Rego-Perez I, Blanco-Garcia F, Fernandez-Moreno M Cells. 2024; 13(11.

PMID: 38891108 PMC: 11172191. DOI: 10.3390/cells13110976.

Infrared Spectroscopy of Synovial Fluid Shows Accuracy as an Early Biomarker in an Equine Model of Traumatic Osteoarthritis.

Panizzi L, Vignes M, Dittmer K, Waterland M, Rogers C, Sano H Animals (Basel). 2024; 14(7).

PMID: 38612225 PMC: 11011100. DOI: 10.3390/ani14070986.

Logistic regression and other statistical tools in diagnostic biomarker studies.

Elkahwagy D, Kiriacos C, Mansour M Clin Transl Oncol. 2024; 26(9):2172-2180.

PMID: 38530558 PMC: 11333519. DOI: 10.1007/s12094-024-03413-8.

Preoperative Synovial Tissue and Synovial Fluid Biomarkers as Predictors for Outcomes After Knee Arthroscopy and ACL Reconstruction: A Narrative Review.

Gottreich J, Katz J, Jones M Orthop J Sports Med. 2024; 12(3):23259671231193370.

PMID: 38496336 PMC: 10943742. DOI: 10.1177/23259671231193370.

Differential Expression of Fibrinogen Alpha and Its Potential Involvement in Osteoarthritis Pathogenesis.

Kumavat R, Kumar V, Biswas S Mol Biotechnol. 2024; 67(1):104-114.

PMID: 38182865 DOI: 10.1007/s12033-023-00983-w.

References

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Carr S, Abbatiello S, Ackermann B, Borchers C, Domon B, Deutsch E . Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014; 13(3):907-17. PMC: 3945918. DOI: 10.1074/mcp.M113.036095. View

Knudson W, Casey B, Nishida Y, Eger W, Kuettner K, Knudson C . Hyaluronan oligosaccharides perturb cartilage matrix homeostasis and induce chondrocytic chondrolysis. Arthritis Rheum. 2000; 43(5):1165-74. DOI: 10.1002/1529-0131(200005)43:5<1165::AID-ANR27>3.0.CO;2-H. View

Keen H, Mease P, Bingham 3rd C, Giles J, Kaeley G, Conaghan P . Systematic review of MRI, ultrasound, and scintigraphy as outcome measures for structural pathology in interventional therapeutic studies of knee arthritis: focus on responsiveness. J Rheumatol. 2010; 38(1):142-54. DOI: 10.3899/jrheum.100377. View

Catterall J, Hsueh M, Stabler T, McCudden C, Bolognesi M, Zura R . Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J Biol Chem. 2011; 287(7):4640-51. PMC: 3281605. DOI: 10.1074/jbc.M111.249649. View

Chandra H, Reddy P, Srivastava S . Protein microarrays and novel detection platforms. Expert Rev Proteomics. 2011; 8(1):61-79. DOI: 10.1586/epr.10.99. View

Campo G, Avenoso A, DAscola A, Prestipino V, Scuruchi M, Nastasi G . Hyaluronan differently modulates TLR-4 and the inflammatory response in mouse chondrocytes. Biofactors. 2012; 38(1):69-76. DOI: 10.1002/biof.202. View

Saxne T, Heinegard D, Wollheim F . Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann Rheum Dis. 1986; 45(6):491-7. PMC: 1001921. DOI: 10.1136/ard.45.6.491. View

Danhof M, de Jongh J, de Lange E, Della Pasqua O, Ploeger B, Voskuyl R . Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2006; 47:357-400. DOI: 10.1146/annurev.pharmtox.47.120505.105154. View

10.

Fleming T, Powers J . Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012; 31(25):2973-84. PMC: 3551627. DOI: 10.1002/sim.5403. View

11.

Amur S, Frueh F, Lesko L, Huang S . Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med. 2010; 2(3):305-11. DOI: 10.2217/17520363.2.3.305. View

12.

Brenner D, Normolle D . Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1918-20. DOI: 10.1158/1055-9965.EPI-07-2619. View

13.

Zhang L, Sinha V, Forgue S, Callies S, Ni L, Peck R . Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn. 2006; 33(3):369-93. DOI: 10.1007/s10928-006-9010-8. View

14.

. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule. Fed Regist. 1992; 57(239):58942-60. View

15.

Homandberg G, Wen C, Hui F . Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthritis Cartilage. 1999; 6(4):231-44. DOI: 10.1053/joca.1998.0116. View

16.

Omenn G, States D, Adamski M, Blackwell T, Menon R, Hermjakob H . Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005; 5(13):3226-45. DOI: 10.1002/pmic.200500358. View

17.

Smith E, Hoy D, Cross M, Vos T, Naghavi M, Buchbinder R . The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014; 73(8):1462-9. DOI: 10.1136/annrheumdis-2013-204680. View

18.

Bauer D, Hunter D, Abramson S, Attur M, Corr M, Felson D . Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006; 14(8):723-7. DOI: 10.1016/j.joca.2006.04.001. View

19.

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003; 138(1):40-4. DOI: 10.7326/0003-4819-138-1-200301070-00010. View

20.

Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, Michaud C . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197-223. DOI: 10.1016/S0140-6736(12)61689-4. View